Veru reports Q1 net loss $8.9M; positive Phase 2b enobosarm data; FC2 business sold for $18M

VERU INC.

Net loss from continuing ops $1.8M ($0.01/sh) vs $7.7M; overall net loss $8.9M ($0.06/sh) vs $8.3M.
R&D expenses rose to $5.7M from $1.7M; SG&A fell to $5.2M from $6.7M; cash $26.6M at Dec 31, 2024.
Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss (p=0.002) with enobosarm+semaglutide.
Enobosarm 3mg+semaglutide preserved 99% of lean mass; 62% relative reduction in stair climb power decline (p=0.0066).
Sold FC2 Female Condom business for $18M; net proceeds ~$12.3M; $9.9M liability extinguished.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.